NovaBridge Biosciences Shares Climb Premarket After FDA Grants Fast Track Designation
By Robb M. Stewart
NovaBridge Biosciences' shares jumped ahead of the opening bell after the cancer therapy being developed by the biotechnology company received the Food and Drug Administration's fast track designation.
In premarket trading, the shares were 9.5% higher at $1.61. The stock had over the last three months fallen almost 50% through Monday's close.
NovaBridge said the FDA granted the designation to givastomig in combination with nivolumab and chemotherapy for the treatment of patients with previously untreated HER2-negative advanced or metastatic gastroesophageal adenocarcinomas whose tumors are both Claudin 18.2 and PD-L1 positive.
Data from a phase 1b trial showed compelling efficacy and tolerability for givastomig in combination with immunochemotherapy, supporting its potential as a premier therapy for gastric cancer, the company said.
Fast track designation is intended to accelerate development and review of therapies for serious conditions with unmet medical need.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
June 16, 2026 08:46 ET (12:46 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States